Using an implantable cardiac monitor to find atrial fibrillation in patients with MINOCA
Official title: Implantable Cardiac Monitor to Detect Atrial Fibrillation in Patients With MINOCA
Run by Insel Gruppe AG, University Hospital Bern · NCT05326828 · Data updated 2026-11-12
This study is testing whether an implantable heart monitor can help find atrial fibrillation in patients who have had a heart attack with non-blocked arteries.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Locations | 2 sites (Bern and 1 other locations) |
| Status | Recruiting |
| Started | May 24, 2022 |
| Main results expected | May 24, 2026 |
| Study ends | May 15, 2031 |
| Registry record updated | October 30, 2024 |
| Trial ID | NCT05326828 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who have experienced an acute myocardial infarction with non-obstructive coronary arteries and no clear underlying cause.
✕Probably not a fit
Patients with known atrial fibrillation or significant coronary artery disease will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on patients who have experienced a myocardial infarction with non-obstructive coronary arteries (MINOCA), a condition that often goes undiagnosed. It aims to systematically assess the underlying causes of MINOCA and the frequency of atrial fibrillation using an implantable cardiac monitor (ICM). Patients will undergo a multidisciplinary work-up and be followed for five years to evaluate clinical outcomes. The study includes both patients who will receive the ICM and those who cannot due to contraindications, allowing for comprehensive data collection.
Why it matters
Potential benefit: If successful, this study could lead to better diagnosis and treatment options for patients with MINOCA by identifying atrial fibrillation as a common underlying cause.
How similar studies have gone: While the use of implantable cardiac monitors is established, this specific approach to assess atrial fibrillation in MINOCA patients is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria ICM group 1. ≥18 years of age 2. Written informed consent 3. Acute myocardial infarction (AMI) type 1 in accordance with the 4th universal definition of myocardial infarction 4. Non-obstructive coronary arteries on angiography defined as the absence of coronary artery stenoses ≥50% in any potential infarct-related artery 5. No clinically overt specific cause for the acute presentation 6. Subendocardial or transmural late gadolinum enhancement (LGE) consistent with an ischemic etiology on cardiac magnetic resonance imaging (CMR) 7. No clear underlying cause of MINOCA and therefore increased probability of atrial fibrillation Exclusion Criteria ICM group: 1. Known atrial fibrillation or atrial flutter 2. History of atrial fibrillation or atrial flutter ablation 3. Known coronary artery disease 4. Previous MI 5. Previous percutaneous coronary intervention (PCI) 6. Previous coronary artery bypass grafting (CABG) 7. Contraindications to CMR (i.e. non-MR-compatible implantable cardiac device, glomerular filtration rate (GFR) \<30 ml/min) 8. Contraindications to ICM implantation 9. Clear underlying cause of MINOCA before ICM implantation Inclusion Criteria non-ICM group: 1. ≥18 years of age 2. Written informed consent 3. AMI type 1 in accordance with the 4th universal definition of myocardial infarction 4. Non-obstructive coronary arteries on angiography defined as the absence of coronary artery stenoses ≥50% in any potential infarct-related artery 5. No clinically overt specific cause for the acute presentation 6. Subendocardial or transmural LGE consistent with an ischemic etiology on CMR Exclusion Criteria non-ICM group: 1. Known coronary artery disease 2. Previous MI 3. Previous PCI 4. Previous CABG 5. Contraindications to CMR (i.e. non-MR-compatible implantable cardiac device, GFR \<30 ml/min)
Where it's running
-
Bern University Hospital Inselspital
Bern, Switzerland Recruiting -
University Hospital Zurich USZ
Zurich, Switzerland Recruiting
Study contacts
- Principal investigator: Lorenz Räber, MD, PhD — Bern University Hospital Inselspital
- Study coordinator: Lorenz Räber, MD, PhD
- Email: lorenz.raeber@insel.ch
- Phone: +41 31 632 50 00
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation
This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.
-
Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II
This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.
-
4D intracardiac echocardiography to guide left atrial appendage occlusion procedures
A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.
-
Thoracoscopic vs Catheter Ablation as the First Rhythm Control in Atrial Fibrillation with a Large Left Atrium
This trial tests whether thoracoscopic surgical ablation is better at keeping atrial fibrillation under control than catheter ablation in people with persistent AF and a large left atrium who have not had an ablation before.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.